Association between tumor necrosis factor-α (TNF-α) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis

ObjectivesTumor necrosis factor (TNF)-α promoter −308G/A polymorphism has been shown to be associated with high TNF-α production and poor response to anti-TNF-α treatment. However, not all patients show a good response to TNF-α antagonists, so this association remains controversial. This study was designed to investigate whether TNF-α promoter −308 G/A polymorphism is associated with responsiveness to anti-TNF therapy in rheumatoid arthritis (RA) patients. The 28-joint count Disease Activity Score (DAS) 28 or the American College of Rheumatology (ACR) improvement criteria 20 were used to measure patient response.MethodsA meta-analysis was performed. Pooled ORs and 95 % CIs were calculated by both dominant and recessive genetic models.ResultsFifteen studies with a total of 2127 patients were included in this meta-analysis. The results showed that patients with the G allele responded better to the treatment (OR = 1.87, 95 % CI 1.26–2.79). A subanalysis showed similar results.ConclusionsBased on the results of this meta-analysis, RA patients with the TNF-α promoter −308 G allele respond better to TNF-α antagonist treatment, suggesting that this allele plays a major role in anti-TNF-alpha treatment response.

[1]  S. Bae,et al.  Associations Between Tumor Necrosis Factor-α (TNF-α) −308 and −238 G/A Polymorphisms and Shared Epitope Status and Responsiveness to TNF-α Blockers in Rheumatoid Arthritis: A Metaanalysis Update , 2010, The Journal of Rheumatology.

[2]  Pilar Barrera,et al.  Tumour necrosis factor α −308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis , 2009, Annals of the rheumatic diseases.

[3]  J. Beyene,et al.  TNF-α −308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis , 2009, The Pharmacogenomics Journal.

[4]  Anne Barton,et al.  Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. , 2008, Human molecular genetics.

[5]  P. Miossec,et al.  Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. , 2008, Arthritis and rheumatism.

[6]  P. Ravaud,et al.  A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[7]  Olfert Landt,et al.  Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[8]  B. Franke,et al.  Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. , 2007, Pharmacogenomics (London).

[9]  I. Georgiou,et al.  Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. , 2007, Rheumatology.

[10]  P. Villiger,et al.  The −308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients , 2007 .

[11]  Y. Lee,et al.  Association of TNF-alpha –308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis , 2006, Rheumatology International.

[12]  J. Aguillón,et al.  Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis , 2006 .

[13]  J. Aguillón,et al.  Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. , 2006, Scandinavian journal of rheumatology.

[14]  J. Fonseca,et al.  Polymorphism at position –308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics , 2005, Annals of the rheumatic diseases.

[15]  S. Bae,et al.  The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. , 2005, Rheumatology.

[16]  H. Tiwari,et al.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. , 2004, Arthritis and rheumatism.

[17]  A. Aguirre,et al.  Tumour necrosis factor‐α (TNF‐α) levels and influence of −308 TNF‐α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis , 2004 .

[18]  N. Balandraud,et al.  Polymorphism at the position -308 of TNF-α gene influences outcome of infliximab therapy in rheumatoid arthritis , 2004, Arthritis Research & Therapy.

[19]  Y. Mándi,et al.  Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. , 2004, Acta microbiologica et immunologica Hungarica.

[20]  J. Cuenca,et al.  Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. , 2004, Scandinavian journal of rheumatology.

[21]  Nathalie Balandraud,et al.  Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[22]  L. Padyukov,et al.  Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[23]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[24]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[25]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[26]  R. Allen.  Polymorphism of the human TNF-α promoter — random variation or functional diversity? , 1999 .

[27]  R. Allen.  Polymorphism of the human TNF-alpha promoter--random variation or functional diversity? , 1999, Molecular immunology.

[28]  J. Belaiche,et al.  Tumour necrosis factor (TNF) gene polymorphism influences TNF‐α production in lipopolysaccharide (LPS)‐stimulated whole blood cell culture in healthy humans , 1998, Clinical and experimental immunology.

[29]  C. Weyand,et al.  The molecular basis of rheumatoid arthritis , 1997, Journal of Molecular Medicine.

[30]  F. Breedveld,et al.  Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? , 1997, British journal of rheumatology.

[31]  M. Homma.  [ACR preliminary definition, of improvement in rheumatoid arthritis]. , 1996, Ryumachi. [Rheumatism].

[32]  D. Rennie,et al.  The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. , 1995, JAMA.

[33]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[34]  I. Chalmers.  The Cochrane Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of Health Care , 1993, Annals of the New York Academy of Sciences.

[35]  M. Feldmann,et al.  TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.

[36]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[37]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[38]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[39]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.